Clinical

Dataset Information

0

Study of Azacitidine and Durvalumab in Advanced Solid Tumors


ABSTRACT: This is a phase 2 study of investigational drug, durvalumab given in combination with azacitidine (CC-486). The main purpose of this phase 2 study is to assess the antitumor activity of azacitidine in combination with durvalumab patients with microsatellite stable colorectal carcinoma (MSS-CRC), platinum resistant epithelial ovarian cancer type II (PR-OC), and estrogen receptor positive and HER2 negative breast cancer.

DISEASE(S): Platinum Resistant Epithelial Ovarian Cancer Type Ii,Microsatellite Stable Colorectal Carcinoma,Carcinoma, Ovarian Epithelial,Colorectal Neoplasms,Estrogen Receptor Positive And Her2 Negative Breast Cancer

PROVIDER: 2218156 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2020-07-26 | GSE147537 | GEO
2022-06-29 | GSE157302 | GEO
2021-06-10 | GSE173839 | GEO
2016-03-30 | E-GEOD-66732 | biostudies-arrayexpress
2017-03-08 | GSE84440 | GEO
2023-05-12 | PXD040761 | Pride
2022-07-15 | GSE207993 | GEO
2022-02-23 | GSE190731 | GEO
2021-07-08 | GSE179674 | GEO
2020-05-28 | GSE151317 | GEO